Project Grant K99CA307630
Award Date 4/14/26
Completion Date 3/31/28
Dollars Obligated $135K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $833,467 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and deploy the ACTIVATE (AI-Driven Clinical Trial Information and Viability Assessment Tool for EHRs) platform. The project, which commenced September 17, 2025 and extends through June 30, 2030, will create open-source artificial intelligence tools designed to improve cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $339,736 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on May 7, 2025, with completion anticipated by April 30, 2030. This award supports research aimed at resolving diagnostic and phenotypic challenges in translocation renal cell carcinoma (TRCC), a rare and aggressive cancer subtype that is frequently misdiagnosed due to phenotypic overlap with...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,641 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. The award supports research training and investigator development focused on advancing understanding of tumor-immune interactions in colorectal cancer through multimodal spatial profiling analysis. The project will utilize highly multiplexed...
- Federal Project Grant Summary Dana-Farber Cancer Institute, Inc. received a $855,249 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with a completion date of August 1, 2032. The award supports research into new approaches for targeting cell cycle proteins, specifically cyclin-dependent kinases (CDKs), as a strategy for cancer treatment. The research addresses current limitations in CDK inhibitor therapy,...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a Project Grant totaling $323,860 under the Cancer Research Manpower program (CFDA 93.398), effective August 18, 2025, with completion by April 30, 2028. This award supports investigative research to elucidate the role of mutagenic DNA repair mechanisms, specifically microhomology-mediated end joining (MMEJ), during cancer cell persistence and the development of acquired drug...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $241,884 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on September 3, 2025, with a completion date of August 31, 2030. This five-year research training and development award supports Dr. Cynthia Hahn's cancer immunology research focused on understanding immune evasion mechanisms in diffuse large B-cell lymphoma (DLBCL) through HLA-E (human...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,075 Project Grant to Dana-Farber Cancer Institute, Inc. under the Cancer Cause and Prevention Research program (CFDA 93.393) on March 24, 2026, with a completion date of February 28, 2031. The grant supports investigative research into the mitotic functions of 53BP1 (tumor protein p53-binding protein 1) and its regulatory protein TIRR, with emphasis on their roles in maintaining genomic stability and regulating...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $275,990 under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. on September 2, 2025, with a completion date of August 31, 2026. This award supports the development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic cancer treatment. The research addresses the critical challenge of poor drug delivery in pancreatic ductal...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $136,266 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective July 14, 2025, through June 30, 2027. The grant funds research aimed at identifying therapeutic strategies to prevent small cell lung cancer (SCLC) histological transformation in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients. The research focuses on understanding the...